A decision support tool to find the best cyclosporine dose when switching from intravenous to oral route in pediatric stem cell transplant patients.

European Journal of Clinical Pharmacology
Vincent LeclercMichel Ducher

Abstract

Managing the pharmacokinetic variability of immunosuppressive drugs after pediatric hematopoietic stem cell transplantation (HSCT) is a clinical challenge. Thus, the aim of our study was to design and validate a decision support tool predicting the best first cyclosporine oral dose to give when switching from intravenous route. We used 10-years pediatric HSCT patients' dataset from 2008 to 2018. A tree-augmented naïve Bayesian network model (method belonging to artificial intelligence) was built with data from the first eight-years, and validated with data from the last two. The Bayesian network model obtained showed good prediction performances, both after a 10-fold cross-validation and external validation, with respectively an AUC-ROC of 0.89 and 0.86, a percentage of misclassified patients of 28.7% and 35.2%, a true positive rate of 0.71 and 0.65, and a false positive rate of 0.12 and 0.14 respectively. The final model allows the prediction of the most likely cyclosporine oral dose to reach the therapeutic target specified by the clinician. The clinical impact of using this model needs to be prospectively warranted. Respecting the decision support tool terms of use is necessary as well as remaining critical about the predict...Continue Reading

References

Nov 1, 1991·Therapeutic Drug Monitoring·A Lindholm
May 1, 1991·International Journal of Bio-medical Computing·S AndreassenK G Olesen
Jan 1, 1988·European Journal of Clinical Pharmacology·A LindholmR Dahlqvist
Mar 1, 1986·Clinical Pharmacokinetics·R J PtachcinskiG J Burckart
May 1, 1996·Pediatrics in Review·B A AtiyehA B Gruskin
Jun 1, 1997·Clinical Pharmacokinetics·G F CooneyK Hoppu
Jan 1, 1997·Transplant International : Official Journal of the European Society for Organ Transplantation·P E WallemacqJ B Otte
Jul 1, 1998·Pharmacology & Toxicology·J HakkolaO Pelkonen
Jan 11, 2000·Clinical Pharmacokinetics·S N de WildtJ N van den Anker
May 18, 2000·Transplantation Proceedings·S Dunn
Apr 18, 2003·International Journal of Clinical Pharmacology and Therapeutics·M KanamoriH Echizen
May 27, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Pamala A JacobsonRichard Brundage
Mar 26, 2004·Transplantation Proceedings·W J Hogan, R Storb
Mar 26, 2004·Transplantation Proceedings·B D Kahan
Jul 29, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·May FakhouryEvelyne Jacqz-Aigrain
Apr 16, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Shigeo FujiYoichi Takaue
Jun 4, 2008·Pharmacogenomics·Dennis A HesselinkTeun van Gelder
Aug 30, 2008·Tropical Medicine & International Health : TM & IH·Kevin M SullivanIbrahim Parvanta
Nov 3, 2009·Bone Marrow Transplantation·A J WillemzeJ M Vossen
Dec 17, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jennifer L McNeerDavid A Jacobsohn
Nov 4, 2010·Journal of Pharmacokinetics and Pharmacodynamics·Marion Bouillon-PichaultMichel Tod
Jun 15, 2012·Emerging Themes in Epidemiology·Katherine J Lee, John B Carlin
Nov 10, 2012·Journal of Pediatric Hematology/oncology·Rachel S Bercovitz, Ralph R Quinones
Jan 1, 2014·Respirology : Official Journal of the Asian Pacific Society of Respirology·Katherine J Lee, Julie A Simpson
Aug 16, 2014·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·E BernardN Bleyzac
Jun 8, 2018·Journal of Evidence-based Medicine·Beatriz Nistal-Nuño
Nov 20, 2018·Diagnostic Cytopathology·Agnieszka OniskoR Marshall Austin
Jan 27, 2019·Evidence-based Mental Health·Colin Aitken, Dimitris Mavridis
May 1, 2019·Fundamental & Clinical Pharmacology·Fouzy KhayiLaurent Bourguignon
May 3, 2019·The Lancet Oncology·Kee Yuan Ngiam, Ing Wei Khor

❮ Previous
Next ❯

Citations

Dec 5, 2020·Journal of Clinical Medicine·Aurelija RadzevičienėEdgaras Stankevičius

❮ Previous
Next ❯

Software Mentioned

Weka
RapidMiner Studio
Orange Canvas

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.